SEPTEMBER, 202619marketing presence in the US, Japan and Vietnam, bringing it closer to customers and opportunities in strategically relevant regions. "This becomes particularly important as pharmaceutical companies reconsider the resilience of global supply chains. Customers seeking additional or alternative sources for complex products require suppliers that already possess the necessary process expertise, quality systems and ability to deliver reliably at commercial scale", mentions Sudhir Vaid.Concord sees second-source opportunities and increasing wallet share with existing customers as meaningful growth avenues. Its broad basket of complex fermentation-based APIs provides scope to deepen relationships rather than compete molecule by molecule."Trust is earned through consistent performance", says Sudhir Vaid, Chairman and Managing Director. For Concord, that translates into quality consistency, supply reliability, technical capability and collaborative engagement. Long-term customer relationships have consequently become an important part of the company's competitive position.Manufacturing expansion is also being accompanied by greater attention to sustainability. Concord is investing in resource optimization, energy efficiency, water conservation, waste reduction and renewable energy alongside responsible manufacturing and ESG governance. As international pharmaceutical customers place greater scrutiny on supply-chain sustainability, these capabilities are becoming increasingly connected with global competitiveness.From Fermentation Manufacturer to Global Biotechnology PartnerConcord's next phase will be driven by a combination of new products, formulations, CDMO expansion, deeper penetration into regulated markets and continued investment in R&D. The ambition is to develop Concord into a more complete solutions provider in fermentation-based biopharmaceuticals - one capable of supporting global pharmaceutical companies through products, development expertise and commercial manufacturing.For Vaid, this next chapter remains connected to the idea with which Concord began. Indian biotechnology, in his view, has the potential to compete through technology creation rather than technology dependence. Concord's own evolution - from transforming a chemical facility at Dholka into a fermentation operation to supplying sophisticated products internationally - has been built around that conviction.Being recognized among the Top Biotechnology Companies therefore carries significance beyond the recognition itself. For Concord, it marks another stage in a journey centered on converting specialized fermentation science into globally competitive pharmaceutical capability. As the company scales CDMO, complex products and international operations, the same three principles that Vaid associates with its legacy - technology, scale and globalization - continue to define where Concord Biotech intends to go next.
< Page 9 | Page 11 >